Organovo's (NYSEMKT:ONVO) investors were rewarded with a pleasant surprise on July 9th as the company announced that it had been approved to uplist on the NYSE MKT. Though its shares began trading on the New York Stock Exchange two days later, on July 11th, the reaction to the news was immediate. Since the release, shares of the 3D bioprinting company are up more than 50% on volume eight times the three month average. Overcoming the OTC stigma through the uplisting catalyst had been expected as it was mentioned on several occasions by CEO Keith Murphy who highlighted the milestone by ringing the opening NYSE bell on July 15th. This switch is a crucial event in Organovo's strives towards...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|